Table 5.
Indicators of quality of life (SF-12, version 2) by LCA-defined subtypes of nonmedical opioid users (N =1,811*)
| Men | Women | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Quality of life: mean score (95% CI) |
C1: Opioid– marijuana |
C2: Opioid–other prescription drugs |
C3: Opioid– marijuana– hallucinogen |
C4: Opioid– polydrug |
F-test p-value |
C1: Opioid– marijuana |
C2: Opioid–other prescription drugs |
C3: Opioid– marijuana– hallucinogen |
C4: Opioid– polydrug |
F-test p-value |
| Sample size | 283 | 85 | 274 | 370 | 343 | 90 | 194 | 172 | ||
| Physical disability | 50.41 (48.93–51.89) | 50.05 (47.78–52.32) | 51.13 (49.65–52.61) | 50.54 (49.12–51.95) | NS | 49.62 (48.23–51.01) | 48.48 (45.51–51.45) | 52.19 (50.46–53.92) | 51.68 (49.77–53.58) | <0.051 |
| Mental disability | 51.35 (49.99–52.72) | 48.43 (45.68–51.18) | 50.66 (49.21–52.12) | 49.19 (48.14–50.24) | <0.051 | 48.93 (47.60–50.27) | 42.59 (39.17–46.02) | 45.50 (43.25–47.76) | 44.62 (42.48–46.76) | <0.01 |
| Physical functioning | 52.25 (51.08–53.42) | 52.08 (49.98–54.18) | 52.51 (51.31–53.71) | 52.07 (50.96–53.17) | NS | 49.95 (48.66–51.24) | 47.78 (44.79–50.78) | 51.81 (50.36–53.26) | 51.28 (49.62–52.95) | <0.051 |
| Physical role | 50.78 (49.51–52.06) | 50.71 (48.07–53.36 | 50.97 (49.39–52.56) | 50.79 (49.30–52.29) | NS | 50.30 (49.04–51.56) | 46.53 (43.20–49.85) | 50.49 (48.93–52.05) | 50.20 (48.59–51.81) | NS |
| Bodily pain | 48.39 (46.59–50.20) | 46.95 (44.27–49.63) | 49.92 (48.35–51.49) | 47.82 (46.18–49.46) | NS | 47.40 (45.80–49.01) | 45.97 (42.78–49.16) | 49.44 (47.59–51.30) | 47.53 (45.45–49.62) | NS |
| General health | 49.86 (48.26–51.45) | 46.75 (43.86–49.63) | 49.00 (47.13–50.86) | 48.64 (47.21–50.06) | NS | 48.95 (47.38–50.53) | 45.85 (42.31–49.38) | 49.48 (47.33–51.63) | 49.03 (46.96–51.11) | NS |
| Vitality | 53.87 (52.31–55.42) | 51.11 (48.15–54.06) | 53.75 (52.41–55.09) | 52.08 (50.86–53.29) | NS | 50.81 (49.61–52.00) | 47.78 (44.38–51.19) | 49.88 (47.93–51.84) | 50.27 (48.49–52.06) | NS |
| Social functioning | 50.31 (48.86–51.75) | 49.53 (46.68–52.38) | 50.93 (49.56–52.29) | 49.33 (48.01–50.64) | NS | 49.44 (47.99–50.90) | 43.89 (40.57–47.21) | 47.71 (45.28–50.14) | 47.14 (45.18–49.09) | <0.051 |
| Emotional role | 50.69 (49.49–51.88) | 48.03 (45.30–50.75) | 50.00 (48.29–51.70) | 49.59 (48.36–50.82) | NS | 49.04 (47.58–50.50) | 42.50 (38.86–46.14) | 47.08 (45.33–48.83) | 44.85 (42.76–46.94) | <0.01 |
| Mental health | 51.06 (49.63–52.48) | 48.69 (46.07–51.32) | 50.42 (48.99–51.85) | 48.76 (47.56–49.95) | NS | 48.08 (46.65–49.52) | 43.05 (40.07–46.02) | 45.53 (43.26–47.80) | 45.12 (42.91–47.34) | <0.01 |
NS: p>0.05;
1
due to multiple comparisons, only results with p<0.01 are discussed. CI: confidence intervals.
*
A total of 4 cases with missing data on SF-12 were not included in the analysis.